(Q54572103)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Emma K Beardsley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Sebastien J Hotte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Scott North

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Eric Winquist

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Christian Kollmannsberger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Som D Mukherjee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Kim N Chi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

23 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1652-1659

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-011-9722-5

8 February 2020

exact match

0 references

cites work

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9722-5

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

21 January 2018

1 reference

12 December 2020

Angiogenesis and prostate cancer: identification of a molecular progression switch

1 reference

12 December 2020

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

12 December 2020

Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells

1 reference

12 December 2020

Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9

1 reference

12 December 2020

10.1007/S10637-011-9722-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21785998%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference